Brief: Renovorx Reports Full Year 2022 Financial Results And Achievement Of Important Phase III Clinical Study Milestone
02/03/2023 14:16
March 2 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND
ACHIEVEMENT OF IMPORTANT PHASE III CLINICAL STUDY MILESTONE
* RENOVORX INC FY LOSS PER SHARE $1.09
* ESTIMATE THAT CURRENT CAPITAL RESOURCES WILL BE SUFFICIENT
TO
FUND OP EXPENSES & CAP EX REQUIREMENTS INTO Q3 2023
Source text for Eikon: ID:nBw90WPtCa
Further company coverage: RNXT.O
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer